Management of Hypertension in CKD: Beyond the Guidelines

Advances in Chronic Kidney Disease

Volumn 22, Issue 2, 2015, Pages 116-122

  Judd, Eric ^a   Calhoun, David A ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Blood pressure; CKD; Hypertension; Resistant; Salt

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST;

AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; DIURETIC THERAPY; GLOMERULONEPHRITIS; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; META ANALYSIS (TOPIC); NONHUMAN; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENOVASCULAR HYPERTENSION; REVIEW; SALT INTAKE; SODIUM RESTRICTION; SYSTEMATIC REVIEW (TOPIC); BLOOD PRESSURE; CHRONOTHERAPY; COMPLICATION; DISEASE COURSE; DISEASE MANAGEMENT; DRUG EFFECTS; KIDNEY FUNCTION TEST; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIET, SODIUM-RESTRICTED; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG CHRONOTHERAPY; HUMANS; HYPERTENSION; KIDNEY FUNCTION TESTS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84923848337     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.12.001     Document Type: Review

References (62)

1. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36(3):646-661.
2. Lash J.P., Go A.S., Appel L.J., et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009, 4(8):1302-1311.
3. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303(20):2043-2050.
4. Cai G., Zheng Y., Sun X., Chen X. Prevalence, awareness, treatment, and control of hypertension in elderly adults with chronic kidney disease: results from the survey of Prevalence, Awareness, and Treatment Rates in Chronic Kidney Disease Patients With Hypertension in China. J Am Geriatr Soc 2013, 61(12):2160-2167.
5. Tozawa M., Iseki K., Iseki C., Kinjo K., Ikemiya Y., Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003, 41(6):1341-1345.
6. Klag M.J., Whelton P.K., Randall B.L., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334(1):13-18.
7. Parati G., Stergiou G., O'Brien E., et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014, 32(7):1359-1366.
8. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013, 34(28):2159-2219.
9. Pogue V., Rahman M., Lipkowitz M., et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 2009, 53(1):20-27.
10. Bangash F., Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2009, 4(3):656-664.
11. Cha R.H., Kim S., Ae Yoon S., et al. Association between blood pressure and target organ damage in patients with chronic kidney disease and hypertension: results of the APrODiTe study. Hypertens Res 2014, 37(2):172-178.
12. Minutolo R., Gabbai F.B., Agarwal R., et al. Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis 2014, 64(5):744-752.
13. Boggia J., Li Y., Thijs L., et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007, 370(9594):1219-1229.
14. Liu M., Takahashi H., Morita Y., et al. Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol Dial Transplant 2003, 18(3):563-569.
15. Minutolo R., Agarwal R., Borrelli S., et al. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med 2011, 171(12):1090-1098.
16. Haruhara K, Tsuboi N, Koike K, et al. Renal histopathological findings in relation to ambulatory blood pressure in chronic kidney disease patients. [e-pub ahead of print, 2014 Sep 18.]. Hypertens Res. 2014. http://dx.doi.org/10.1038/hr.2014.140.
17. Mojon A., Ayala D.E., Pineiro L., et al. Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int 2013, 30(1-2):145-158.
18. Hermida R.C., Smolensky M.H., Ayala D.E., et al. Abnormalities in chronic kidney disease of ambulatory blood pressure 24 h patterning and normalization by bedtime hypertension chronotherapy. Nephrol Dial Transplant 2014, 29(6):1160-1167.
19. Agarwal R., Andersen M.J. Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension 2005, 46(3):514-520.
20. Higashi Y., Oshima T., Ozono R., et al. Nocturnal decline in blood pressure is attenuated by NaCl loading in salt-sensitive patients with essential hypertension: noninvasive 24-hour ambulatory blood pressure monitoring. Hypertension 1997, 30(2 Pt 1):163-167.
21. Uzu T., Sakaguchi M., Yokomaku Y., et al. Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clin Exp Nephrol 2009, 13(4):300-306.
22. Townsend R.R., Wimmer N.J., Chirinos J.A., et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 2010, 23(3):282-289.
23. Gates P.E., Tanaka H., Hiatt W.R., Seals D.R. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004, 44(1):35-41.
24. Logan A.G., Perlikowski S.M., Mente A., et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001, 19(12):2271-2277.
25. Sakaguchi Y., Shoji T., Kawabata H., et al. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study. Clin J Am Soc Nephrol 2011, 6(5):995-1000.
26. Langstan J.B., Guyton A.C., Douglas B.H., Dorsett P.E., Russel A., McCaa R.E. Effect of changes in salt intake on arterial pressure and renal function in partially nephrectomized dogs. Circ Res 1963, 12:508-513.
27. Guyton A.C. Blood pressure control-special role of the kidneys and body fluids. Science 1991, 252(5014):1813-1816.
28. Ying W.Z., Sanders P.W. Dietary salt modulates renal production of transforming growth factor-beta in rats. Am J Physiol 1998, 274(4 Pt 2):F635-F641.
29. Fellner R.C., Cook A.K., O'Connor P.M., Zhang S., Pollock D.M., Inscho E.W. High-salt diet blunts renal autoregulation by a reactive oxygen species-dependent mechanism. Am J Physiol Renal Physiol 2014, 307(1):F33-F40.
30. Smyth A., O'Donnell M.J., Yusuf S., et al. Sodium intake and renal outcomes: a systematic review. Am J Hypertens 2014, 27(10):1277-1284.
31. American Diabetes Associations Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(suppl 1):S11-S66.
32. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013, 31(10):1925-1938.
33. Go A.S., Bauman M.A., Coleman King S.M., et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension 2014, 63(4):878-885.
34. Clinical practice guideline for the evaluation and management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012, 2(5):337-414. Group KDIGOKBPW.
35. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311(5):507-520.
36. Krause T., Lovibond K., Caulfield M., McCormack T., Williams B. Management of hypertension: summary of NICE guidance. BMJ 2011, 343:d4891.
37. Weber M.A., Schiffrin E.L., White W.B., et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014, 16(1):14-26.
38. Taler S.J., Agarwal R., Bakris G.L., et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 2013, 62(2):201-213.
39. Upadhyay A., Earley A., Haynes S.M., Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011, 154(8):541-548.
40. Kovesdy C.P., Bleyer A.J., Molnar M.Z., et al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med 2013, 159(4):233-242.
41. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51(6):1403-1419.
42. Bax L., Woittiez A.J., Kouwenberg H.J., et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009, 150(12):840-848. w150-w841.
43. Wheatley K., Ives N., Gray R., et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009, 361(20):1953-1962.
44. Cooper C.J., Murphy T.P., Cutlip D.E., et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014, 370(1):13-22.
45. McMahon E.J., Bauer J.D., Hawley C.M., et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol 2013, 24(12):2096-2103.
46. Slagman M.C., Waanders F., Hemmelder M.H., et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011, 343:d4366.
47. Vogt L., Waanders F., Boomsma F., de Zeeuw D., Navis G. Effectsof dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008, 19(5):999-1007.
48. Sodium Intake in Populations: Assessment of Evidence 2013, Institute of Medicine, The National Academies Press, Washington, DC.
49. Anderson C.A., Ix J.H. Sodium reduction in CKD: suggestively hazardous or intuitively advantageous?. J Am Soc Nephrol 2013, 24(12):1931-1933.
50. Agarwal R., Sinha A.D. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens 2012, 6(5):299-308.
51. Dussol B., Moussi-Frances J., Morange S., Somma-Delpero C., Mundler O., Berland Y. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich) 2012, 14(1):32-37.
52. Carter B.L., Ernst M.E., Cohen J.D. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004, 43(1):4-9.
53. Crespo J.J., Pineiro L., Otero A., et al. Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease. Chronobiol Int 2013, 30(1-2):159-175.
54. Hermida R.C., Ayala D.E. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 2009, 54(1):40-46.
55. Hermida R.C., Ayala D.E., Mojon A., Fernandez J.R. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010, 27(8):1629-1651.
56. Hermida R.C., Ayala D.E., Mojon A., Fernandez J.R. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011, 22(12):2313-2321.
57. Hermida R.C., Ayala D.E., Mojon A., Fernandez J.R. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011, 34(6):1270-1276.
58. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49(4):839-845.
59. Vaclavik J., Sedlak R., Plachy M., et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011, 57(6):1069-1075.
60. Pisoni R., Acelajado M.C., Cartmill F.R., et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens 2012, 26(8):502-506.
61. Shavit L., Lifschitz M.D., Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012, 81(10):955-968.
62. Judd E., Calhoun D.A. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens 2014, 28(8):463-468.